Overview
The goal of this observational study is to evaluate the safety and efficacy of adebrelimab in the perioperative and advanced-stage treatment of small cell lung cancer （SCLC） under real-world conditions. The main questions it aims to answer are:
- The safety of adebrelimab treatment in patients with advanced SCLC under real-world conditions, with a specific focus on the incidence of grade ≥3 immune-related adverse events. Safety monitoring begins when patients start receiving adebrelimab treatment and continues until 90 days after the last dose of adebrelimab.
- Observe and evaluate the efficacy of adebrelimab in patients with small cell lung cancer under real-world conditions. This includes overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, the study seeks to further explore the impact of patient baseline characteristics, such as brain metastases or liver metastases, and biomarkers on prognosis.
Eligibility
Inclusion Criteria:
- Histologically or cytologically confirmed extensive-stage small cell lung cancer;
- Age ≥ 18 years;
- The investigator determines that the patient is eligible for or is already receiving adebrelimab treatment.
Exclusion Criteria:
- Patients concurrently receiving other immune-modulating drugs or therapies;
- Patients currently participating in other interventional studies;
- Patients with concurrent other malignancies;
- Patients with missing key study-related data.
